Wednesday - April 22, 2026

Category Archives: Science

Cernum Biosciences Peptide Store Recognized in Independent Review for Transparency and Quality

Cernum Biosciences review 2026 highlights peptide purity testing, transparency standards, and third-party verification in research compounds Cernum Biosciences has been recognized in a 2026 independent review for its quality standards, transparency, and overall customer confidence in the peptide space. The … Continue reading →

British Software Company Achieves Pioneering Breakthrough, Making It Possible to Now Run a 24 Billion Parameter AI Large Language Model Entirely Offline on the iPhone

Until recently, the idea of running a model of this size privately on a smartphone would have been regarded as technically out of reach for current flagship handsets. LiberaGPT now brings that capability to iPhone, ensuring that prompts and responses … Continue reading →

Ibogaine by David Dardashti Aligns with New Federal”Right to Try” Directives to Target the NeurologicalRoots of Childhood Trauma

MIAMI, FL – April 20, 2026 – Following the recent Executive Order to fast-track access to investigational psychedelics, Ibogaine by David Dardashti announces a renewed focus on advanced clinical insights for treating the neurological impact of severe childhood trauma. As … Continue reading →

Pulmonary Hypertension associated Interstitial Lung Disease Market Size (7MM) was ~USD 3 Billion in 2025 and is projected to expand at a CAGR of 3.9% through 2036, estimates DelveInsight

DelveInsight’s “Pulmonary Hypertension associated Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of the Pulmonary Hypertension associated Interstitial Lung Disease, historical and forecasted epidemiology and the Pulmonary Hypertension associated Interstitial Lung Disease … Continue reading →

Familial Chylomicronemia Syndrome Clinical Trial Pipeline Expands as 5+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Familial Chylomicronemia Syndrome Pipeline Insights 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Familial Chylomicronemia Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Metastatic Colorectal Cancer Treatment Clinical Trial Pipeline Shows Potential with Active Contributions from 150+ Key Companies | DelveInsight

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2026” report provides comprehensive insights about 150+ companies and 180+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Lupus Nephritis Clinical Trial Pipeline Accelerates as 35+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Lupus Nephritis Pipeline Insight 2026” report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Congenital Hyperinsulinism Clinical Trial Pipeline Expands as 4+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Congenital Hyperinsulinism Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Congenital Hyperinsulinism pipeline landscape. It covers the Congenital Hyperinsulinism pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

End-stage Renal Disease Clinical Trial Pipeline Accelerates as 4+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “End-stage Renal Disease Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the End-stage Renal Disease pipeline landscape. It covers the End-stage Renal Disease pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →